Research Analysts Set Expectations for SCYNEXIS Q2 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Equities research analysts at Brookline Capital Markets lifted their Q2 2026 EPS estimates for SCYNEXIS in a research report issued to clients and investors on Friday, May 1st. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.10). The consensus estimate for SCYNEXIS’s current full-year earnings is ($0.34) per share. Brookline Capital Markets also issued estimates for SCYNEXIS’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at ($0.10) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at ($0.78) EPS.

Several other equities research analysts also recently weighed in on the stock. reiterated a “buy” rating on shares of SCYNEXIS in a research note on Monday, March 9th. Wall Street Zen raised shares of SCYNEXIS from a “hold” rating to a “buy” rating in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.

SCYNEXIS Stock Performance

Shares of SCYX opened at $0.98 on Tuesday. SCYNEXIS has a fifty-two week low of $0.57 and a fifty-two week high of $1.31. The company has a market capitalization of $43.95 million, a price-to-earnings ratio of -5.79 and a beta of 1.12. The firm has a 50-day simple moving average of $0.90 and a 200-day simple moving average of $0.76.

SCYNEXIS (NASDAQ:SCYX) last announced its earnings results on Wednesday, March 4th. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.04). SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.The business had revenue of $17.20 million for the quarter, compared to analyst estimates of $8.10 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SCYX. Jane Street Group LLC purchased a new position in SCYNEXIS during the second quarter worth about $27,000. Sequoia Financial Advisors LLC purchased a new position in SCYNEXIS during the third quarter worth about $41,000. GSA Capital Partners LLP raised its holdings in SCYNEXIS by 95.2% during the third quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after purchasing an additional 50,916 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in SCYNEXIS by 4.2% during the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after purchasing an additional 14,689 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in SCYNEXIS by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after purchasing an additional 29,775 shares in the last quarter. 54.37% of the stock is owned by hedge funds and other institutional investors.

About SCYNEXIS

SCYNEXIS, Inc is a late?stage biopharmaceutical company focused on developing and commercializing novel anti?infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.